China Meheco: Subsidiary Tianfang Pharmaceutical's Nicardipine Tablets intend to be selected for the 11th batch of national centralized drug procurement

Zhitong
2025.10.28 09:53

China Meheco announced that its subsidiary Tianfang Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement, and its Nicardipine tablets are expected to be selected. The product specification is 5mg, indicated for angina pectoris, with a packaging quantity of 48 tablets/box, and the proposed winning price is 2.59 yuan/box. The procurement period is 3 years, from 2026 to December 31, 2028. Tianfang Pharmaceutical's audited operating income for the year 2024 is approximately 52.47 million yuan, and the unaudited operating income for the first half of 2025 is approximately 15.82 million yuan. If awarded the bid, it will help expand product sales scale, increase market share, and have a positive impact on the company's future performance

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer